Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference
Bellicum Pharmaceuticals (Nasdaq: BLCM) announced that Rick Fair, President and CEO, will present at the B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022, at 4 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bellicum Pharmaceuticals (Nasdaq: BLCM) announced that Rick Fair, President and CEO, will present at the B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022, at 4 p.m. ET. A live webcast will be available on the company's website, with a replay accessible afterward. Bellicum specializes in controllable cellular immunotherapies for cancer, with innovative GoCAR-T® candidates like BPX-601 and BPX-603 that aim to enhance CAR-T cell therapy efficacy.
Details
News Market Reaction – BLCM
The recorded move for BLCM in the trading session of this news was +3.37%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the B. Riley Securities 2022 Virtual Oncology Conference. A corporate presentation is scheduled for Thursday, January 27, 2022 at 4 p.m. ET / 1 p.m. PT.
A live webcast of the presentation will be available from the Investor Relations section of the company website at Events & Presentations - Bellicum with a replay available shortly after the live event.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com or follow us on Twitter or LinkedIn.
Investors:
Robert H. Uhl
Managing Director
ICR Westwicke
858-356-5932
Robert.uhl@westwicke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.